keyword
MENU ▼
Read by QxMD icon Read
search

Mrd

keyword
https://www.readbyqxmd.com/read/28215040/who-should-receive-a-transplant-for-acute-lymphoblastic-leukaemia
#1
REVIEW
Rishi Dhawan, David I Marks
Allogeneic haematopoietic cell transplantation continues to be an important curative therapy for acute lymphoblastic leukaemia (ALL). Traditionally accepted indications for allografting adult ALL patients need reevaluation in light of outcomes with paediatric-like intensive regimens. Minimal residual disease status and oncogenetics can be used for restratification of standard risk patients. A greater body of data on haematopoietic cell transplantation (HCT) outcomes from haploidentical and cord blood donor sources has been generated in recent years...
February 18, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28212374/the-effect-of-body-mass-index-at-diagnosis-on-clinical-outcome-in-children-with-newly-diagnosed-acute-lymphoblastic-leukemia
#2
H M Eissa, Y Zhou, J C Panetta, E K Browne, S Jeha, C Cheng, M V Relling, D Campana, C-H Pui, H Inaba
The impact of body mass index (BMI) at diagnosis on treatment outcome in children with acute lymphoblastic leukemia (ALL) is controversial. We studied 373 children with ALL enrolled on the Total XV study, which prospectively used minimal residual disease (MRD) for risk assignment. MRD on day 19 and at the end of remission induction (day 46), cumulative incidence of relapse/refractory disease (CIR), event-free survival (EFS) and overall survival (OS) were evaluated using sets of four, three and two subgroups based on BMI at diagnosis, along with BMI percentile change during remission induction...
February 17, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28205342/functional-benefits-and-patient-satisfaction-with-upper-blepharoplasty-evaluated-by-objective-and-subjective-outcome-measures
#3
Agnes Galbo Jacobsen, Brian Brost, Henrik Vorum, Janos Hargitai
PURPOSE: To investigate the functional benefits and patient satisfaction with upper blepharoplasty in patients meeting the Danish visitation guidelines for upper blepharoplasty from the Danish Health and Medicines Authority (Sundhedsstyrelsen). METHODS: Before and 3 months after upper blepharoplasty, the following investigations were made: (i) a standard eye examination, (ii) photographic documentation with a normal camera and the infrared camera of a Spectralis Optical Coherence Tomograph and (iii) measurements of the upper visual fields using the blepharoptosis test of Octopus 900...
February 15, 2017: Acta Ophthalmologica
https://www.readbyqxmd.com/read/28205262/modern-multiple-myeloma-therapy-deep-sustained-treatment-response-and-good-clinical-outcomes
#4
REVIEW
O Landgren, K Iskander
In the USA at the beginning of this century, the average overall survival in patients with multiple myeloma was about 3 years. Around that time, three drugs (bortezomib, lenalidomide and thalidomide) were introduced for the treatment of multiple myeloma and, in 2012, carfilzomib received accelerated approval by the US Food and Drug Administration (FDA). Driven by access to better drugs, median overall survival in younger patients (aged <50 years) was >10 years by 2014. The FDA approved 14 new drugs for the treatment of cancer in 2015; four of these were approved for the treatment of myeloma (panobinostat, daratumumab, elotuzumab and ixazomib)...
February 16, 2017: Journal of Internal Medicine
https://www.readbyqxmd.com/read/28205134/minimal-residual-disease-in-acute-lymphoblastic-leukemia-how-to-recognize-and-treat-it
#5
REVIEW
Nicholas J Short, Elias Jabbour
In recent years, the identification of minimal residual disease (MRD) that persists after chemotherapy has emerged as the most powerful tool in determining the prognosis of patients with ALL, often superseding historically relevant prognostic factors. Multiple methods to detect MRD exist, each with their own advantages and disadvantages. Multiparameter flow cytometry and quantitative polymerase chain reaction are the most commonly used methods of MRD detection in clinical practice, although there is promise in the use of more sensitive assays utilizing next-generation sequencing that may be able to further refine MRD-based risk stratification...
January 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28203343/maintenance-therapy-in-multiple-myeloma
#6
REVIEW
Prerna Mewawalla, Abhishek Chilkulwar
Despite recent advances, multiple myeloma remains an incurable disease. Induction therapy followed by autologous transplantation has become the standard of care. The idea of maintenance therapy in multiple myeloma is not new. Starting with chemotherapy in 1975, to interferon in 1998, to novel agents recently, a multitude of agents have been explored in patients with multiple myeloma. In spite of the novel agents, multiple myeloma continues to be an incurable disease with the progression-free survival after autologous transplant rarely exceeding 3 years...
February 2017: Therapeutic Advances in Hematology
https://www.readbyqxmd.com/read/28166825/the-dynamics-of-runx1-runx1t1-transcript-levels-after-allogeneic-hematopoietic-stem-cell-transplantation-predict-relapse-in-patients-with-t-8-21-acute-myeloid-leukemia
#7
Ya-Zhen Qin, Yu Wang, Lan-Ping Xu, Xiao-Hui Zhang, Huan Chen, Wei Han, Yu-Hong Chen, Feng-Rong Wang, Jing-Zhi Wang, Yao Chen, Xiao-Dong Mo, Xiao-Su Zhao, Ying-Jun Chang, Kai-Yan Liu, Xiao-Jun Huang
BACKGROUND: The optimal monitoring schedules and cutoff minimal residual disease (MRD) levels for the accurate prediction of relapse at all time points after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain unclear in patients with t(8;21) acute myeloid leukemia (AML). METHODS: RUNX1-RUNX1T1 transcript levels were measured in bone marrow samples collected from 208 patients at scheduled time points after transplantation (1530 samples in total)...
February 6, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28163010/use-of-wilms-tumor-1-gene-expression-as-a-reliable-marker-for-prognosis-and-minimal-residual-disease-monitoring-in-acute-myeloid-leukemia-with-normal-karyotype-patients
#8
Irena Marjanovic, Teodora Karan-Djurasevic, Milena Ugrin, Marijana Virijevic, Ana Vidovic, Dragica Tomin, Nada Suvajdzic Vukovic, Sonja Pavlovic, Natasa Tosic
BACKGROUND: Acute myeloid leukemia with normal karyotype (AML-NK) represents the largest group of AML patients classified with an intermediate prognosis. A constant need exists to introduce new molecular markers for more precise risk stratification and for minimal residual disease (MRD) monitoring. PATIENTS AND METHODS: Quantitative assessment of Wilms tumor 1 (WT1) gene transcripts was performed using real-time polymerase chain reaction. The bone marrow samples were collected at the diagnosis from 104 AML-NK patients and from 34 of these patients during follow-up or disease relapse...
January 11, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28159598/predictive-value-of-pretransplantation-molecular-minimal-residual-disease-assessment-by-wt1-gene-expression-in-flt3-positive-acute-myeloid-leukemia
#9
Anna Candoni, Federico De Marchi, Francesca Zanini, Maria Elena Zannier, Erica Simeone, Eleonora Toffoletti, Alexsia Chiarvesio, Michela Cerno, Carla Filì, Francesca Patriarca, Renato Fanin
The FMS-like tyrosine kinase 3 (FLT3) mutation in acute myeloid leukemia (AML) is a negative prognostic factor and, in these cases, allogeneic stem cell transplantation (allo-SCT) can represent an important therapeutic option, especially if performed in complete remission (CR). However, it is increasingly clear that not all cytological CRs (cCRs) are the same and that minimal residual disease (MRD) before allo-SCT could have an impact on AML outcome. Unfortunately, FLT3, due its instability of expression, is still not considered a good molecular MRD marker...
February 1, 2017: Experimental Hematology
https://www.readbyqxmd.com/read/28151719/neoadjuvant-enzalutamide-prior-to-prostatectomy
#10
Bruce Montgomery, Maria S Tretiakova, Anthony Michael Joshua, Martin E Gleave, Neil Fleshner, Glenn J Bubley, Elahe A Mostaghel, Kim N Chi, Daniel Lin, Martin Sanda, William Novotny, Kenneth Wu, Philip W Kantoff, Brett Marck, Steve Plymate, Steven P Balk, Peter S Nelson, Alvin M Matsumoto, Rosina T Lis, Adam Kibel, Gabriel P Haas, Andrew Krivoshik, Alison Hannah, Mary-Ellen Taplin
PURPOSE: Prostate cancer is dependent on androgen receptor (AR) activation. Optimal AR antagonism may effectively cytoreduce local disease and suppress or eliminate micrometastases. We evaluated neoadjuvant therapy prior to prostatectomy with the potent AR antagonist enzalutamide (enza) either alone or in combination with dutasteride and leuprolide (enza/dut/LHRHa). EXPERIMENTAL DESIGN: Forty-eight of 52 men with intermediate or high-risk localized prostate cancer proceeded to prostatectomy after neoadjuvant enza or enza/dut/LHRHa for 6 months...
November 9, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28151710/new-developments-in-diagnosis-prognosis-and-assessment-of-response-in-multiple-myeloma
#11
EDITORIAL
Ola Landgren, S Vincent Rajkumar
Over the past few years, the management of multiple myeloma has changed. We have new guidelines regarding how to set the diagnosis, when to initiate therapy, and how to monitor treatment response. In 2014, the updated International Myeloma Working Group (IMWG) diagnostic criteria changed the definition of multiple myeloma from being a disease defined by symptoms to a disease defined by biomarkers. Today, modern combination therapies have reported up to 60% to 80% of patients reaching a complete response. As a logical and necessary step forward, investigators have explored strategies to detect minimal residual disease (MRD) and its correlation with clinical outcomes...
November 15, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28151709/progress-and-paradigms-in-multiple-myeloma
#12
EDITORIAL
Kenneth C Anderson
Remarkable progress has been achieved in multiple myeloma, and patient median survival has been extended 3- to 4-fold. Specifically, there have been 18 newly approved treatments for multiple myeloma in the past 12 years, including seven in 2015, and the treatment paradigm and patient outcome have been transformed. The definition of patients benefitting from these therapies has been broadened. Response criteria now include minimal residual disease (MRD), assessed in bone marrow by multicolor flow cytometry or sequencing, and by imaging for extramedullary disease...
November 15, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28138921/absolute-lymphocyte-count-alc-after-induction-treatment-predicts-survival-of-pediatric-patients-with-acute-lymphoblastic-leukemia
#13
Tamas Farkas, Judit Müller, Daniel J Erdelyi, Monika Csoka, Gabor T Kovacs
Absolute Lymphocyte Count (ALC) has been recently established as a prognostic factor of survival in pediatric Acute Lymphoblastic Leukemia (ALL). A retrospective analysis of 132 patients treated according the BFM - ALLIC 2002 protocol was performed in a single institution. A possible association between ALC values and Overall Survival (OS) or Event-Free Survival (EFS) was evaluated at multiple time points during induction chemotherapy. ALC higher than 350 cells/μL measured on the 33th day of induction was associated with better Overall- and Event-Free Survival in both Kaplan-Meier (OS 88...
January 30, 2017: Pathology Oncology Research: POR
https://www.readbyqxmd.com/read/28123303/vtd-melphalan-is-well-tolerated-and-results-in-very-high-rates-of-stringent-cr-and-mrd-negative-status-in-multiple-myeloma
#14
Kalyan Nadiminti, Kamal Kant Singh Abbi, Sarah L Mott, Lindsay Dozeman, Annick Tricot, Allyson Schultz, Sonya Behrends, Fenghuang Zhan, Guido Tricot
The addition of cytotoxic drugs to high-dose melphalan as a preparative regimen for autologous stem cell transplantation in multiple myeloma has not resulted in superior activity. Although novel agents have significantly improved outcome in multiple myeloma, their role in preparative regimens remains largely unknown. We have evaluated the toxicity and efficacy of combining bortezomib, thalidomide, and dexamethasone with high-dose melphalan. An institutional review board-approved retrospective analysis was performed on 100 consecutive patients receiving 153 transplants; 53 had tandem transplants; 64 patients received early transplants; and 36 had salvage transplantation...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28123246/flow-cytometric-detection-of-minimal-residual-disease-in-b-lineage-acute-lymphoblastic-leukemia-by-using-mrd-lite-panel
#15
Tathagata Chatterjee, Venkatesan Somasundaram
BACKGROUND: Normal B lymphoid precursors that express CD19, CD10, and/or CD34 are highly sensitive to corticosteroids and after two weeks of remission-induction therapy, they form less than 0.01% of the bone marrow population. More than 0.01% of such cells indicate minimal residual disease (MRD). MRD "lite" panel uses only three antibodies, namely CD19, CD10, and CD34 for MRD detection in cases of B-lineage acute lymphoblastic leukemia (B-ALL) expressing CD19, CD10, and/or CD34 by flow cytometry...
January 2017: Medical Journal, Armed Forces India
https://www.readbyqxmd.com/read/28116786/the-combination-of-bortezomib-with-chemotherapy-to-treat%C3%A2-relapsed-refractory-acute-lymphoblastic-leukaemia-of-childhood
#16
Alice Bertaina, Luciana Vinti, Luisa Strocchio, Stefania Gaspari, Roberta Caruso, Mattia Algeri, Valentina Coletti, Carmelo Gurnari, Mariateresa Romano, Maria Giuseppina Cefalo, Katia Girardi, Valentina Trevisan, Valentina Bertaina, Pietro Merli, Franco Locatelli
Achieving complete remission (CR) in childhood relapsed/refractory acute lymphoblastic leukaemia (ALL) is a difficult task. Bortezomib, a proteasome inhibitor, has in vitro activity against ALL blasts. A phase I-II trial, reported by the Therapeutic Advances in Childhood Leukaemia and Lymphoma (TACL) consortium, demonstrated that bortezomib with chemotherapy has acceptable toxicity and remarkable activity in patients with relapsed ALL failing 2-3 previous regimens. We evaluated bortezomib in combination with chemotherapy in 30 and 7 children with B-cell precursor (BCP) and T-cell ALL, respectively...
January 24, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28115371/a-review-of-the-management-of-adults-with-t-cell-acute-lymphoblastic-leukemia
#17
David I Marks, Clare Rowntree
T-cell acute lymphoblastic leukemia (ALL) is a rare disease in adults with inferior survival outcomes compared to those seen in pediatric patients. Although potentially curable with about 50% survival at 5 years, adult patients with relapsed disease have dismal outcomes with less than 10% of patients surviving long term. This review will discuss the diagnosis and management of adult patients with newly diagnosed T-cell ALL with an emphasis on the immunophenotypic and genetic analyses required to assign prognosis, risk stratify and guide post remission therapy...
January 23, 2017: Blood
https://www.readbyqxmd.com/read/28115277/impact-of-post-transplant-response-and-minimal-residual-disease-on-survival-in-myeloma-with-high-risk-cytogenetics
#18
Rajshekhar Chakraborty, Eli Muchtar, Shaji K Kumar, Dragan Jevremovic, Francis K Buadi, David Dingli, Angela Dispenzieri, Suzanne R Hayman, William J Hogan, Prashant Kapoor, Martha Q Lacy, Nelson Leung, Morie A Gertz
The impact of depth of response and minimal residual disease (MRD) status on survival is not well defined in multiple myeloma (MM) with high-risk (HR) cytogenetics, due to low representation of such patients in clinical trials. We have evaluated the impact of post-transplant stringent complete response (sCR) and MRD-status on progression-free survival (PFS) and overall survival (OS) in 185 consecutive MM patients with HR FISH cytogenetics undergoing upfront autologous stem cell transplantation (ASCT) between 2007 and 2015 in our institution...
January 20, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28110381/minimal-residual-disease-in-acute-myeloid-leukemia
#19
REVIEW
Pamela J Sung, Selina M Luger
New technology and improved understanding of the pathogenesis of acute leukemias have allowed for sensitive detection of minimal residual disease (MRD). Despite many years of research demonstrating the prognostic value of MRD, there is no standard of care for measurement of MRD in acute myeloid leukemia. The techniques for assessment are continuing to improve at a rapid pace; however, the benefit of risk-adapted approaches for MRD positive disease remains a major question. This review focuses on recent methodological advances for MRD detection, the role of MRD in prognostication, and current application of the available evidence in guiding therapy decisions...
January 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28107815/upfront-haploidentical-transplant-for-acquired-severe-aplastic-anemia-registry-based-comparison-with-matched-related-transplant
#20
Lan-Ping Xu, Song Jin, Shun-Qing Wang, Ling-Hui Xia, Hai Bai, Su-Jun Gao, Qi-Fa Liu, Jian-Min Wang, Xin Wang, Ming Jiang, Xi Zhang, De-Pei Wu, Xiao-Jun Huang
BACKGROUND: Haploidentical donor (HID) hematopoietic stem cell transplantation (HSCT) is an alternative treatment method for severe aplastic anemia (SAA) patients lacking suitable identical donors and those who are refractory to immunosuppressive therapy (IST). The current study evaluated the feasibility of upfront haploidentical HSCT in SAA patients. METHODS: We conducted a multicenter study based on a registry database. One hundred fifty-eight SAA patients who underwent upfront transplantation between June 2012 and September 2015 were enrolled...
January 21, 2017: Journal of Hematology & Oncology
keyword
keyword
15643
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"